Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2020’, provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis

– The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeome Corp

Accendatech Au Pty Ltd

AdAlta Ltd

Afimmune Biopharma Ltd

Algernon Pharmaceuticals Inc

Altavant Sciences Inc

Altay Therapeutics Inc

Amgen Inc

Amplia Therapeutics Ltd

AnaMar AB

Angion Biomedica Corp

Apaxen

Aqua Therapeutics Co Ltd

Aqualung Therapeutics Corp

Ark Biosciences Inc

Arroyo BioSciences LLC

Asahi Kasei Pharma Corp

AstraZeneca Plc

Atrapos Therapeutics LLC

AusBio Ltd

Avalyn Pharma Inc

BerGenBio ASA

Blade Therapeutics Inc

Boehringer Ingelheim International GmbH

Bonac Corp

BreStem Therapeutics Inc

Bristol-Myers Squibb Co

Celdara Medical LLC

CellCure

Certa Therapeutics Pty Ltd

Chiesi Farmaceutici SpA

Chrysalis Pharma SAS

Citryll BV

CohBar Inc

Collaborations Pharmaceuticals Inc

Compugen Ltd

CrystalGenomics Inc

Daewoong Pharmaceutical Co Ltd

EmphyCorp Inc

Epitracker Inc

Ergon Pharmaceuticals LLC

ethris GmbH

F. Hoffmann-La Roche Ltd

FibroGen Inc

FibroStatin SL

Galapagos NV

Galecto Biotech AB

GenKyoTex SA

Global Blood Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

HEC Pharm Co Ltd

iBio Inc

Imago Pharmaceuticals Inc

Indalo Therapeutics Inc

Inventiva

iOnctura SA

Ionis Pharmaceuticals Inc

Isarna Therapeutics GmbH

Iterion Therapeutics

Jiangsu Hengrui Medicine Co Ltd

JW Pharmaceutical Corp

Kadmon Corp LLC

KBP BioSciences Co Ltd

Kither Biotech Srl

Kyorin Pharmaceutical Co Ltd

Lamellar Biomedical Ltd

LifeMax Laboratories Inc

Lignamed LLC

Liminal BioSciences Inc

LTT Bio-Pharma Co Ltd

Lung Therapeutics Inc

Max Biopharma Inc

MDI Therapeutics Inc

Medicenna Therapeutics Corp

Metagone Biotech Inc

Metera Pharmaceuticals Inc

Miragen Therapeutics Inc

Mission Therapeutics Ltd

Moerae Matrix Inc

Morphic Holding Inc

National Institutes of Pharmaceutical R&D Co Ltd

NB Health Laboratory Co Ltd

New Amsterdam Sciences Inc

Nogra Pharma Ltd

Novartis AG

Novo Nordisk AS

Nuformix Plc

Oasis Pharmaceuticals LLC

OliX Pharmaceuticals Inc

OncoArendi Therapeutics SA

Opsidio LLC

OptiKira LLC

OROX BioSciences Inc

Osteoneurogen Inc

Palo BioFarma SL

Panorama Research Inc

Pharmaxis Ltd

Pharmicell Co Ltd

Pliant Therapeutics Inc

Prasan Pharmaceutical Consultants LLC

PRISM Pharma Co Ltd

Pulmatrix Inc

RDS2 Solutions Inc

Re-Pharm Ltd

Redx Pharma Plc

Regenasome Pty Ltd

Rejuvenation Technologies Inc

Reviva Pharmaceuticals Inc

Ribomic Inc

Roivant Sciences Ltd

Saje Pharma LLC

Samumed LLC

Segue Therapeutics LLC

Shionogi & Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Silurian Pharmaceuticals Inc

Suzhou Zelgen Biopharmaceutical Co Ltd

SynDevRx Inc

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Telocyte LLC

Theravance Biopharma Inc

TiumBio Co Ltd

TRACON Pharmaceuticals Inc

Translate Bio Inc

Unity Biotechnology Inc

Vectus Biosystems Ltd

Vicore Pharma AB

X-Rx Inc

Xfibra Inc

Yungjin Pharm Co Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Introduction

Idiopathic Pulmonary Fibrosis - Overview

Idiopathic Pulmonary Fibrosis - Therapeutics Development

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development

Idiopathic Pulmonary Fibrosis - Drug Profiles

Idiopathic Pulmonary Fibrosis - Dormant Projects

Idiopathic Pulmonary Fibrosis - Discontinued Products

Idiopathic Pulmonary Fibrosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Abeome Corp, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Accendatech Au Pty Ltd, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by AdAlta Ltd, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Afimmune Biopharma Ltd, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Algernon Pharmaceuticals Inc, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Altavant Sciences Inc, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Altay Therapeutics Inc, H1 2020

Idiopathic Pulmonary Fibrosis – Pipeline by Amgen Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports